In cisplatin-resistant ovarian cancer cell line SKOV-3, upregulation of leukotriene B4 and its receptor leukotriene B4 receptor-2 (BLT2) leads to activation of STAT-3 and IL-6 and depletion of BLT2 increased cell sensitivity to cisplatin chemotherapy (Park et al., 2016). This evidence concerns the gene LTB4R2 and ovarian cancer.